Table 3 Main parameters and effects of of rhGH or rhGH + Anastrazole administration in the 24 adolescent males
|  | GH alone | GH + Anastrazole | P |
|---|---|---|---|
N | 12 | 12 | Â |
GH dosage (mg/k.d) | 0.073 ± 0.09 | 0.076 ± 0.01 | NS |
Duration of GH administration (mo) | 11.5 ± 5 | 19 ± 5.9 | 0.02 |
Age at end of GH (yrs) | 16.2 ± 1.1 | 16.8 ± 0.7 | 0.08 |
Mean IGF1 (SDS) | 0.55 ± 0.3 | 0.65 ± 0.6 | NS |
Delta IGF1 (SDS)* | 1.02 ± 0.3 | 0.97 ± 0.5 | NS |
Predicted height** | Â | Â | Â |
 cm | 158.2 ± 2.9 | 157.9 ± 3.8 | NS |
 SDS | - 2.84 ± 0.5 | - 2.9 ± 0.6 | NS |
Final height | Â | Â | Â |
 cm | 164.2 ± 5.6 | 168.4 ± 2.6 | 0.02 |
 SDS | - 1.8 ± 0.9 | - 1.1 ± 0.4 | 0.02 |
Growth velocity Year 1 (cm/yr) | 4.9 ± 4 | 6.7 ± 2.8 | 0.18 |
Growth velocity Year 2 (cm/yr) | 1.2 ± 0.5 | 3.6 ± 2.7 | 0.008 |
Height increase from GH onset (HtG1) (cm) | 7.8 ± 5 | 12.7 ± 5.6 | 0.02 |
Height gain vs PAH (HtG2) (cm) | 5.9 ± 4.5 | 10.5 ± 5.2 | 0.02 |